Scholarlink

<p>Acute liver injury is accompanied by the development of oxidative stress, inflammatory reactions, and high mortality. The use of traditional hepatoprotectors is limited by their low bioavailability and nonspecific distribution. This review summarizes data from domestic and international sources (2005 – 2025) on the use of nanosomal forms (liposomes, niosomes, phytosomes, etc.) for the delivery of hepatoprotectors, including <i>S</i>-adenosylmethionine, <i>N</i>-acetylcysteine, ursodeoxycholic acid, silymarin, curcumin, L-ornithine-L-aspartate, and taurine. Nanosomal forms increase the stability and hepatic accumulation of active ingredients, reduce systemic toxicity, and enhance pharmacodynamics in preclinical models. Clinical data for most drugs are currently limited to individual early-phase studies. The results can be used for planning preclinical experiments and clinical trials of new nanoforms of hepatoprotectors for acute liver injury.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Nanosomal Forms of Hepatoprotectors in Acute Liver Injury: A Review

  • 期刊论文

  • 发表日期：

    2026年1月1日

查看全文
  • S. V. Tsaregorodtsev,
  • I. V. Maev,
  • A. V. Zaborovskiy,
  • N. A. Pyataev,
  • L. A. Tararina,
  • A. G. Mulyar,
  • M. Yu. Savelyev,
  • A. V. Vychkin,
  • N. V. Kheladze,
  • I. M. Dadayeva

摘要

Acute liver injury is accompanied by the development of oxidative stress, inflammatory reactions, and high mortality. The use of traditional hepatoprotectors is limited by their low bioavailability and nonspecific distribution. This review summarizes data from domestic and international sources (2005 – 2025) on the use of nanosomal forms (liposomes, niosomes, phytosomes, etc.) for the delivery of hepatoprotectors, including S-adenosylmethionine, N-acetylcysteine, ursodeoxycholic acid, silymarin, curcumin, L-ornithine-L-aspartate, and taurine. Nanosomal forms increase the stability and hepatic accumulation of active ingredients, reduce systemic toxicity, and enhance pharmacodynamics in preclinical models. Clinical data for most drugs are currently limited to individual early-phase studies. The results can be used for planning preclinical experiments and clinical trials of new nanoforms of hepatoprotectors for acute liver injury.